Latest filing published 14 Dec 2022 for Harmony Biosciences Holdings, Inc., €360k.
Filing timeline
BuySaleInsider track record
Closed purchases
Based on 2 purchases whose 90-day window has closed (published at least 91 days ago), the same population our ranking model reads.
Purchases by company
Since each purchase
- +126.9%Entry US$7.15 · Close at T+365 US$16.22
- +50.3%Entry US$7.00 · Close at T+365 US$10.52
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Andreas Wicki: trading record in brief
This profile gathers the share dealings of Andreas Wicki across 3 companies, led by Pacira BioSciences, Inc., Harmony Biosciences Holdings, Inc. and Viela Bio, Inc. We count 118 filings; the first trade dates from 8 February 2011 and the latest from 14 December 2022.
The open-market side counts 4 purchases for €12.9M alongside 108 sales for €237.1M. Netting one side against the other leaves €224.2M of net selling. A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant. Besides market trades, the filings include 2 share grants. 2022 to date brings no purchases and 24 sales.
The median purchase comes to €1.4M.
The latest filing, published on 14 December 2022, reports an open-market sale of €360k in Harmony Biosciences Holdings, Inc. The last insider purchase was made public on 9 October 2019, 2,587 days ago. The median gap between a trade and its publication by SEC (Form 4) is 2 days. The legal deadline for a Form 4 is two business days after the transaction. Sales are harder to read than purchases, since they often meet personal needs such as tax or diversification. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.
Companies and markets linked to Andreas Wicki
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
- 6,320 shares@ US$60.130.3% of flowCommon StockSEC:0001104659-22-127089:1
- 130 shares@ US$60.000.0% of flowCommon StockSEC:0001104659-22-127089:2
- 22,391 shares@ US$60.362.2% of flowCommon StockSEC:0001104659-22-127089:0
- 77,853 shares@ US$61.237.8% of flowCommon StockSEC:0001104659-22-125246:0
- 10,961 shares@ US$60.100.5% of flowCommon StockSEC:0001104659-22-119662:1
- 40,317 shares@ US$59.104.0% of flowCommon StockSEC:0001104659-22-119662:0
- 15,301 shares@ US$58.050.7% of flowCommon StockSEC:0001104659-22-117342:1
- 95,242 shares@ US$58.804.6% of flowCommon StockSEC:0001104659-22-117342:2
- 18,865 shares@ US$60.012.0% of flowCommon StockSEC:0001104659-22-117342:0
- 254,141 shares@ US$59.4412.5% of flowCommon StockSEC:0001104659-22-115029:1
- 157,950 shares@ US$58.817.8% of flowCommon StockSEC:0001104659-22-115029:2
- 164,676 shares@ US$58.8117.0% of flowCommon StockSEC:0001104659-22-115029:0
- 20,745 shares@ US$53.670.9% of flowCommon StockSEC:0001104659-22-088896:1
- 71,447 shares@ US$52.613.0% of flowCommon StockSEC:0001104659-22-088896:2
- 486,360 shares@ US$53.9444.6% of flowCommon StockSEC:0001104659-22-088896:0
- 12,640 shares@ US$52.670.5% of flowCommon StockSEC:0001104659-22-086804:1
- 29,482 shares@ US$52.571.2% of flowCommon StockSEC:0001104659-22-086804:2
- 30,464 shares@ US$52.902.7% of flowCommon StockSEC:0001104659-22-086804:0
- 75,217 shares@ US$45.802.5% of flowCommon StockSEC:0001104659-22-033022:1
- 70,370 shares@ US$44.142.3% of flowCommon StockSEC:0001104659-22-033022:2
- 140,000 shares@ US$45.4910.1% of flowCommon StockSEC:0001104659-22-033022:0
- 328,927 shares@ US$40.529.8% of flowCommon StockSEC:0001104659-22-030268:1
- 175,000 shares@ US$41.015.3% of flowCommon StockSEC:0001104659-22-030268:2
- 92,501 shares@ US$40.245.8% of flowCommon StockSEC:0001104659-22-030268:0
- 2,585 shares@ US$40.080.2% of flowCommon StockSEC:0001104659-21-148779:1
25 of 116 declarations
